OncoCyte Corp (OCX)
2.525
+0.04
(+1.81%)
USD |
NASDAQ |
Apr 29, 16:00
2.51
-0.02
(-0.59%)
After-Hours: 20:00
OncoCyte Debt to Equity Ratio: 0.00 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.0065 |
| March 31, 2022 | 0.0166 |
| Date | Value |
|---|---|
| December 31, 2021 | 0.0201 |
| September 30, 2021 | 0.0169 |
| June 30, 2021 | 0.0199 |
| March 31, 2021 | 0.0332 |
| December 31, 2020 | 0.1164 |
| September 30, 2020 | 0.1191 |
| June 30, 2020 | 0.1037 |
| March 31, 2020 | 0.0837 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Sep 2022
0.1191
Maximum
Sep 2020
0.0335
Average
0.0168
Median
Debt to Equity Ratio Benchmarks
| Fonar Corp | 0.0008 |
| XWELL Inc | 0.00 |
| ProPhase Labs Inc | 0.2077 |
| Applied DNA Sciences Inc | 0.00 |
| Veracyte Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 74.89M |
| Total Liabilities (Quarterly) | 54.42M |
| Shareholders Equity (Quarterly) | 20.47M |
| Current Ratio | 1.487 |